INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte Corp. (INCY) Tuesday said that phase 3 RA-BEACON study of their Rheumatoid arthritis drug Baricitinib met its primary endpoint.
The primary endpoint of the study was to achieve improved ACR20 response compared to placebo after 12 weeks of treatment. ACR20 response refers to more than 20 percent improvement measured under the American College of Rheumatology criteria.
The drug is also designed for use in treatment of psoriasis and diabetic nephropathy and is under phase 2 studies for the same.
RA-BEACON study enrolled 527 patients who had previously failed at least one anti-TNF therapy, the companies said in a news release.
These patients are generally considered to be the least responsive to subsequent treatments said David Ricks, Lilly senior vice president.
The participants of this study were given 1 of 2 doses of once daily baricitinib or placebo in addition to their background conventional disease-modifying anti-rheumatic drug therapy.
Copyright RTT News/dpa-AFX